Area of research
Hematology · Molecular Biology
Research interest
Research focused on Myeloid leukemia and Oncology, with related work in IDH1, Cancer research, Minimal residual disease. Notable publications include 'Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML', 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo', and 'Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations'.
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Clec12a is required for the pathogenesis of NUP98::NSD1 AML
Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo